Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

Table 4

NRS-11 ratings of pain intensity from baseline to pre-cycle 3/5.

Patient	Tumor pain			Overall pain
	Baseline	PC3/5	Diff	Baseline	PC3/5	Diff
009	10	10	0	10	10	0
013	5	2^†	−3	5	1	−4
016	10	8	−2	10	8	−2
019	5	0	−5	5	0	−5
Mean	7.5	5	2.5	7.5	4.75	2.75

Ratings from the pre-cycle 5 evaluation. Note. Clinically meaningful change is ≥2 points (0–3 = mild pain; 4–6 = moderate pain; 7–10 = severe pain).